Novartis AG ADR (NVS)vsZevra Therapeutics Inc. (ZVRA)
NVS
Novartis AG ADR
$164.98
-1.85%
HEALTHCARE · Cap: $303.67B
ZVRA
Zevra Therapeutics Inc.
$10.53
-5.73%
HEALTHCARE · Cap: $597.10M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 42057% more annual revenue ($57.36B vs $136.07M). ZVRA leads profitability with a 42.8% profit margin vs 17.5%. NVS appears more attractively valued with a PEG of 3.84. ZVRA earns a higher WallStSmart Score of 66/100 (B-).
NVS
Hold48
out of 100
Grade: D+
ZVRA
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$164.98
$69.42 premium
Margin of Safety
+64.0%
Fair Value
$23.52
Current Price
$10.53
$12.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Attractively priced relative to earnings
Keeps 43 of every $100 in revenue as profit
Strong operational efficiency at 42.3%
Revenue surging 53.3% year-over-year
Conservative balance sheet, low leverage
Every $100 of equity generates 27 in profit
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.4x book value
4.7% revenue growth
Grey zone — moderate risk
Smaller company, higher risk/reward
Expensive relative to growth rate
Earnings declined 88.4%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : ZVRA
The strongest argument for ZVRA centers on P/E Ratio, Profit Margin, Operating Margin. Profitability is solid with margins at 42.8% and operating margin at 42.3%. Revenue growth of 53.3% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : ZVRA
The primary concerns for ZVRA are Market Cap, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
NVS profiles as a value stock while ZVRA is a growth play — different risk/reward profiles.
ZVRA carries more volatility with a beta of 0.98 — expect wider price swings.
ZVRA is growing revenue faster at 53.3% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
ZVRA scores higher overall (66/100 vs 48/100), backed by strong 42.8% margins and 53.3% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Zevra Therapeutics Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Zevra Therapeutics, Inc., a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company is headquartered in Celebration, Florida.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?